Phase I Trial Characterizing the Pharmacokinetic Profile of N-803, a Chimeric IL-15 Superagonist, in Healthy Volunteers

Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma

(2021) Jennifer A. Foltz et al.   CLINICAL CANCER RESEARCH

Unleashing Natural Killer Cells in the Tumor Microenvironment–The Next Generation of Immunotherapy?

(2020) Aviad Ben-Shmuel et al.   Frontiers in Immunology

Bench-to-bedside translation of interleukin-15 for immunotherapy: principles and challenges

(2020) Chalet Tan et al.   Expert Opinion on Drug Delivery

First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation

(2018) Rizwan Romee et al.   BLOOD

IL-2 and Beyond in Cancer Immunotherapy

(2018) John M. Wrangle et al.   JOURNAL OF INTERFERON AND CYTOKINE RESEARCH

ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial

(2018) John M Wrangle et al.   LANCET ONCOLOGY

High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy

(2018) Carsten Krieg et al.   NATURE MEDICINE

The potential and promise of IL-15 in immuno-oncogenic therapies

(2017) Tanya O. Robinson et al.   IMMUNOLOGY LETTERS

IL-15 superagonist/IL-15RαSushi-Fc fusion complex (IL-15SA/IL-15RαSu-Fc; ALT-803) markedly enhances specific subpopulations of NK and memory CD8+ T cells, and mediates potent anti-tumor activity against murine breast and colon carcinomas

(2016) Peter S. Kim et al.   Oncotarget

FlowSOM: Using self-organizing maps for visualization and interpretation of cytometry data

(2015) Sofie Van Gassen et al.   CYTOMETRY PART A

Redistribution, Hyperproliferation, Activation of Natural Killer Cells and CD8 T Cells, and Cytokine Production During First-in-Human Clinical Trial of Recombinant Human Interleukin-15 in Patients With Cancer

(2015) Kevin C. Conlon et al.   JOURNAL OF CLINICAL ONCOLOGY

Preassociation of IL-15 with IL-15R -IgG1-Fc Enhances Its Activity on Proliferation of NK and CD8+/CD44high T Cells and Its Antitumor Action

(2014) S. Dubois et al.   JOURNAL OF IMMUNOLOGY

IL-2: The First Effective Immunotherapy for Human Cancer

(2014) S. A. Rosenberg   JOURNAL OF IMMUNOLOGY

Efficacy and Mechanism-of-Action of a Novel Superagonist Interleukin-15: Interleukin-15 Receptor  Su/Fc Fusion Complex in Syngeneic Murine Models of Multiple Myeloma

(2013) W. Xu et al.   CANCER RESEARCH

Normalization of mass cytometry data with bead standards

(2013) Rachel Finck et al.   CYTOMETRY PART A

Multiobjective evolutionary algorithms to identify highly autocorrelated areas: the case of spatial distribution in financially compromised farms

(2011) Carlos R. García-Alonso et al.   ANNALS OF OPERATIONS RESEARCH

IL-15:IL-15 receptor alpha superagonist complex: High-level co-expression in recombinant mammalian cells, purification and characterization

(2011) Kai-ping Han et al.   CYTOKINE

Novel Human Interleukin-15 Agonists

(2009) X. Zhu et al.   JOURNAL OF IMMUNOLOGY

High antitumor activity of RLI, an interleukin-15 (IL-15)-IL-15 receptor   fusion protein, in metastatic melanoma and colorectal cancer

(2009) A. Bessard et al.   MOLECULAR CANCER THERAPEUTICS

Interleukin-15/Interleukin-15R  Complexes Promote Destruction of Established Tumors by Reviving Tumor-Resident CD8+ T Cells

(2008) M. Epardaud et al.   CANCER RESEARCH